[Asia Economy Reporter Chunhee Lee] Engchem Life Sciences announced on the 7th that it presented the results of the Phase 2 clinical trial of the new drug candidate 'EC-18' for chemoradiation-induced oral mucositis (CRIOM) at the 2022 American Society of Clinical Oncology (ASCO).
The presentation at ASCO, held from the 3rd to the 7th of this month (local time) in Chicago, was delivered by Dr. Christina Henson, a radiation oncology specialist at the University of Oklahoma. The Phase 2 clinical trial results confirmed the safety, tolerability, and efficacy of EC-18 in patients with severe oral mucositis caused by chemoradiation therapy for head and neck cancer. According to the results, the incidence of severe oral mucositis (SOM) in the treatment group taking EC-18 during the drug administration period decreased by 37.1% compared to the placebo group.
Attendees of the presentation noted the high unmet medical need for oral mucositis, a condition with no approved drugs, through various questions about EC-18's mechanism of action, chemical structure, and administration method, expressing anticipation for the Phase 3 clinical trial.
Professor Henson explained, "Since there are currently no FDA-approved drugs or treatments in the United States, oral medications like EC-18 will be a necessary treatment option for patients."
Engchem Life Sciences is actively pursuing technology export of EC-18 and plans to complete the protocol design required for Phase 3 clinical trials through consultations with the FDA, and jointly apply for an Investigational New Drug (IND) application with a global pharmaceutical company based on the results.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
